Invesaro

Stocks Health care BIXT

OTC · Health care

Bioxytran, Inc (BIXT)

It posted a net loss of $3.5M. At June 30, 2026 it held $177.4K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch BIXT in 60 seconds
Price
$0.02
+4.98% on the day · September 25, 2026
52-week range $0.02 to $0.09
Market cap
$2.4M

What Bioxytran, Inc does

Bioxytran, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker BIXT.

Revenue and profit by year

Net income
FY18: -$296.4K -$296.4K FY18FY19: -$1.9M -$1.9M FY19FY20: -$2.5M -$2.5M FY20FY21: -$4M -$4M FY21FY22: -$2.5M -$2.5M FY22FY23: -$4.5M -$4.5M FY23FY24: -$2.4M -$2.4M FY24FY25: -$2.1M -$2.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/a-$1.8M-$2.1M-$0.02n/a
2024n/a-$2.2M-$2.4M-$0.02n/a
2023n/a-$3.8M-$4.5M-$0.03n/a
2022n/a-$2.4M-$2.5M-$0.02n/a
2021n/a-$4.2M-$4M-$0.04n/a
2020n/a-$1.3M-$2.5M-$0.03n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Bioxytran, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.01 versus $0.00.
  2. August 11, 2026
  3. May 15, 2026
    Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.02 versus -$0.02.
  4. April 15, 2026
    Annual report 10-K · period to December 31, 2025Diluted EPS -$0.02 versus -$0.02.
  5. April 1, 2026
  6. March 20, 2026
  7. March 13, 2026
  8. March 2, 2026
  9. February 17, 2026
  10. February 11, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 18, 2025. Insider transactions on SEC

Insider trades

What the people running Bioxytran, Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
November 18, 2025 Hoberman Alan MDirector Bought 210,000 $0.60 $126K Form 4
November 14, 2025 Utter AndersDirector Received as pay 38,588 $0.35 $13.5K Form 4
November 14, 2025 Conaway Dale HDirector Received as pay 38,588 $0.35 $13.5K Form 4
November 14, 2025 Milanova RadkaDirector Received as pay 38,588 $0.35 $13.5K Form 4
November 14, 2025 Hoberman Alan MDirector Received as pay 38,588 $0.35 $13.5K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BIXT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

We have not read this company's Schedule 13D and 13G filings yet.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

7 insiders reported holding 44,211,731 shares in total, about $932.9K at the last price.

HolderSharesAs of
Platt DavidCEO, Director, 10% owner 20,038,903 October 24, 2024
Soderquist OlaCFO, 10% owner 14,376,456 October 25, 2024
Sheikh MichaelCCO, 10% owner 8,214,720 October 25, 2024
Hoberman Alan MDirector 626,207 November 18, 2025
Conaway Dale HDirector 379,177 November 14, 2025
Utter AndersDirector 372,580 November 14, 2025
Milanova RadkaDirector 203,688 November 14, 2025

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BIXT

What does Bioxytran, Inc do?

Bioxytran, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker BIXT.

Is Bioxytran, Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $3.5M.

When did Bioxytran, Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare BIXT with

Compare BIXT with any company

Follow BIXT

Get an email when Bioxytran, Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow BIXT: get an email when it files

Where the numbers come from

Financial figures are the values Bioxytran, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.